Where do Relay Therapeutics, Inc.'s ratios come from?

Every ratio is computed from Relay Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Profitability
Operating margin	-1,971.5%+1,751pp	-3,722.1%-2,262pp	-1,460.1%+20,211pp	-21,670.9%-9,631pp
Net margin	-1,800.5%+1,574pp	-3,374.7%-2,036pp	-1,338.6%+19,698pp	-21,036.1%-9,023pp
EBITDA margin	-1,948.3%+1,719pp	-3,667.5%-2,228pp	-1,439.4%+19,932pp	-21,371.8%-9,461pp
Free cash flow margin	-1,536%+974pp	-2,509.5%-1,318pp	-1,191.7%+16,082pp	-17,273.9%-14,703pp
Returns
Return on equity	-41.1%+3.0pp	-44.2%-4.0pp	-40.2%-8.7pp	-31.4%+12.4pp
Return on assets	-37%+2.3pp	-39.4%-4.2pp	-35.2%-7.6pp	-27.6%+12.7pp
Return on invested capital	-49.7%+4.9pp	-54.6%-5.5pp	-49.1%-9.2pp	-40%+34.4pp
Efficiency
Asset turnover	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Liquidity
Current ratio	22.6×+6.7×	16×-9.5×	25.4×+9.4×	16×-24.1×
Quick ratio	22.6×+6.7×	16×-9.5×	25.4×+9.4×	16×-24.1×
Cash ratio	3.3×+0.8×	2.5×-2.3×	4.7×+2.4×	2.4×-9.1×
Leverage
Debt-to-equity	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Debt-to-assets	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Valuation
Market capitalization	$1.47B+113%	$689.62M-48.9%	$1.35B-25.3%	$1.81B-45.7%
Enterprise value	$1.41B+130%	$613.83M-51.3%	$1.26B-26.5%	$1.71B-44.2%
Price / sales	95.5×+26.6×	68.9×+16.1×	52.8×-1,256×	1,308.6×+211×
Price / book	2.6×+1.7×	0.9×-0.9×	1.8×-0.1×	1.9×-1.8×
EV / sales	92.1×+30.8×	61.3×+12.0×	49.3×-1,191×	1,240.5×+228×
Free cash flow yield	-16.1%+20.3pp	-36.4%-13.9pp	-22.6%-9.4pp	-13.2%-10.9pp
Earnings yield	-18.9%+30.1pp	-49%-23.6pp	-25.3%-9.3pp	-16.1%-5.1pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Relay Therapeutics, Inc.'s ratios come from?: Every ratio is computed from Relay Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.